Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiviral chemotherapy.

D O White

    The Medical Journal of Australia
    |June 9, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Antiviral chemotherapy, including nucleoside analogues like acyclovir and interferons, shows promise for treating viral diseases. However, many agents are still experimental and not yet widely available.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Analysis of the requirements for class II-restricted T cell recognition of a single determinant reveals considerable diversity in the T cell response and degeneracy of peptide binding to I-Ed.

    Journal of immunology (Baltimore, Md. : 1950)·1995
    Same author

    Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

    Archives of virology·1995
    Same author

    Conservation of determinants for class II-restricted T cells within site E of influenza virus hemagglutinin and factors influencing their expression.

    Journal of virology·1993
    Same author

    Extension of a minimal T cell determinant allows relaxation of the requirement for particular residues within the determinant.

    International immunology·1991
    Same author

    Probing the idiotype/anti-idiotype antibody interaction with a set of synthetic peptide homologues.

    Immunology letters·1991
    Same author

    The stoichiometry of binding between monoclonal antibody molecules and the hemagglutinin of influenza virus.

    Virology·1990
    Same journal

    Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

    The Medical journal of Australia·2026
    Same journal

    Striving for Racial Equity in Oral Cancer Research: A Case Study.

    The Medical journal of Australia·2026
    Same journal

    Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

    The Medical journal of Australia·2026
    Same journal

    Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

    The Medical journal of Australia·2026
    Same journal

    Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

    The Medical journal of Australia·2026
    Same journal

    Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

    The Medical journal of Australia·2026
    See all related articles

    Area of Science:

    • Virology
    • Pharmacology
    • Biotechnology

    Background:

    • Antiviral chemotherapy has advanced through logical drug design strategies.
    • Second-generation nucleoside analogues, such as acyclovir, are effective against herpesviruses.

    Purpose of the Study:

    • To review the progress and current status of antiviral chemotherapy.
    • To evaluate the potential of nucleoside analogues and interferons in treating viral infections.

    Main Methods:

    • Review of existing literature on antiviral agents.
    • Discussion of advancements in nucleoside analogue development.
    • Consideration of recombinant DNA technology's impact on interferon production and clinical trials.

    Main Results:

    Related Experiment Videos

    • Acyclovir and similar nucleoside analogues demonstrate proven efficacy against herpesviruses.
    • Recombinant DNA technology has made human interferons more accessible for clinical trials.
    • Most discussed antiviral agents are promising but not yet fully proven.

    Conclusions:

    • Nucleoside analogues like acyclovir should be integrated into standard medical practice.
    • Further controlled clinical trials are needed for interferons and other promising antiviral agents.
    • Availability of novel antiviral therapies may be limited in certain regions.